AI 탑재 종양 진단용 바이브 CT 스캐너 시장 : 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI oncology vibe CT scanners market size is projected to expand from USD 0.86 billion in 2025 and USD 1.05 billion in 2026 to USD 2.92 billion by 2031, registering a CAGR of 22.70% between 2026 to 2031.

This report is Segmented by Component (Hardware, Software, Services), Deployment (Conventional AI-Enhanced CT, Spectral CT, Photon-Counting CT, Interventional CT), Application (Oncology Diagnosis, Tumor Monitoring, RT Planning, Trials), End User (Hospitals, Imaging Centers, Cancer Centers, Research Institutes), and Geography (North America, Europe, Asia-Pacific, MEA, South America).

Global AI Oncology Vibe CT Scanners Market Trends and Insights

Rising Oncology Imaging Demand: Global Cancer Incidence Sets the Baseline

The AI oncology vibe CT scanners market is being lifted by the sheer scale of global cancer incidence. GLOBOCAN 2024 reported 20.6 million new cancer diagnoses and 9.8 million cancer deaths worldwide, and the same release projected incidence to reach 34.4 million cases by 2050. Lung cancer remained the highest-incidence cancer with 2.6 million new cases and the leading cause of cancer mortality with 1.9 million deaths, which reinforces CT use across initial diagnosis, staging, and follow-up care. The Lancet Oncology also projected diagnosed cancer incidence to rise from 13.58 million cases in 2025 to 19.32 million cases by 2050, with the largest burden growth expected in lower-resource settings. In the United States alone, the National Cancer Institute estimated 2.04 million new cancer cases in 2025, which supports continued imaging investment even when hospital capital budgets remain tight. This pattern means the AI oncology vibe CT scanners market is not only expanding in premium hospitals, but is also drawing more demand for capable mid-tier systems in countries that need oncology-grade image quality at more practical procurement levels.

AI Assisted Protocol Optimization: Closing the Radiologist Productivity Gap

The AI oncology vibe CT scanners market is also gaining from tools that reduce the workload on radiologists and imaging teams. The World Health Organization reported acute workforce shortages in 70% of low- and middle-income countries, which makes automation in scan selection, reconstruction, and reporting more valuable in day-to-day oncology imaging. In November 2025, Mosaic Clinical Technologies said early reader studies tied to its Cognita Imaging acquisition showed up to 52% higher cancer detection, up to 4 times fewer significant diagnostic errors, and up to 76% lower radiologist read time with AI-radiologist collaboration. United Imaging Intelligence presented its uAI Insight Image-to-Report agent at ECR 2026 and said it could detect up to 73 thoracic findings from a single chest CT scan while generating a structured preliminary report automatically. As a result, the AI oncology vibe CT scanners market is increasingly being evaluated not only on image quality, but also on whether a platform can help facilities recruit, retain, and support radiologists in a tight labor environment. That shift gives vendors with integrated workflow tools a stronger position in procurement discussions than vendors offering imaging gains alone.

High Capital Cost of Premium CT Platforms: Capex Thresholds Limit Mid-Market Penetration

The AI oncology vibe CT scanners market still faces a clear capital barrier at the premium end. The draft indicates that premium photon-counting CT installations often exceed USD 3 million, which places them beyond the normal procurement range of many district hospitals and independent imaging centers. This burden is heavier in public systems that prioritize imaging volume and broad access over advanced platform capability. It also creates a two-tier pattern where large, well-funded institutions move faster into full platform replacement while many mid-tier sites continue upgrading existing scanners with software. In practice, this means the AI oncology vibe CT scanners market does not convert all technology interest into immediate hardware revenue. It also explains why software deployment can expand more quickly than complete scanner replacement in several countries.

Other drivers and restraints analyzed in the detailed report include:

1. Photon Counting and Spectral Precision Gains: Detector Physics Rewrites Oncology Staging
2. Radiation Dose Reduction Pressure: ALARA Standards Drive AI Reconstruction Adoption
3. Oncology Workflow Automation and Triage: Faster Throughput Becomes a Buying Criterion
4. Reimbursement Support for Quantitative Imaging: Documentation Value Moves Closer to Revenue Value
5. Integration Burden Across PACS, RIS, and EHR Environments: Where AI Features Stall in Practice

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Hardware held 68.2% of the AI oncology vibe CT scanners market in 2025, which reflects the capital-intensive nature of detector assemblies, X-ray tube systems, gantries, and workstations in premium oncology imaging setups. This large base also reflects the need for physical replacement as photon-counting systems start to displace older energy-integrating installations in tertiary and academic settings. In the AI oncology vibe CT scanners industry, hardware still anchors vendor revenue because high-end hospitals continue to invest in systems that support better lesion characterization and stronger quantitative output. Services remain important because long-term maintenance, managed imaging agreements, and remote support create recurring income tied to the installed base. The draft also notes that Siemens Healthineers has used Value Partnership models to position lifecycle management as part of the sales offer, which shows that service depth can influence large account retention.

Software is the fastest-growing component at a 23.2% CAGR through 2031, which makes it the most dynamic profit pool within the AI oncology vibe CT scanners market. This growth is being supported by AI reconstruction tools, quantitative imaging analytics, and cloud-enabled workflow platforms that can be sold to both new and existing CT users. The strategic value is clear because vendor-neutral software can extend across mixed scanner fleets without waiting for full system replacement. United Imaging Intelligence said its uAI Clinical Portal now includes more than 60 AI applications across oncology, neuroradiology, and cardiovascular imaging, which illustrates how vendors are broadening the software layer around imaging hardware. Subtle Medicalalso showed the commercial path for vendor-neutral deployment when it announced FDA-cleared CT image enhancement software across more than 1,300 scanners worldwide. In the AI oncology vibe CT scanners industry, that pattern widens addressable demand because software can monetize installed systems that are not ready for premium hardware replacement yet.

Conventional AI-enhanced CT held 58.2% of the AI oncology vibe CT scanners market share in 2025, showing that the installed base of upgraded energy-integrating detector systems still defines current deployment volume. That share does not indicate weak interest in newer systems. It reflects the long replacement cycle that shapes CT purchasing across hospitals and imaging centers. Spectral CT and interventional CT continue to serve important but narrower roles in tissue characterization, treatment monitoring, biopsies, and other targeted oncology workflows. In the AI oncology vibe CT scanners market, conventional AI-enhanced CT remains the practical bridge between current installed assets and the next detector cycle.

Photon-counting CT is the fastest-growing deployment mode at a 23.8% CAGR through 2031, and this part of the AI oncology vibe CT scanners market is advancing because clinical evidence and regulatory support are now moving in the same direction. Research published in Insights into Imaging in 2025 described strong advantages across thoracic, abdominal, and musculoskeletal oncology, including better lesion visibility and lower contrast needs. GE HealthCare received FDA clearance for Photonova Spectra in March 2026 and said the system processes up to 50 times more data than conventional CT through its Deep Silicon detector and 8-bin energy resolution design. Philips received FDA clearance for Verida in April 2026 and positioned it as the first AI-powered detector-based spectral CT, adding further weight to the premium shift. These launches matter because they push the AI oncology vibe CT scanners market toward systems that can support both better oncology imaging and stronger software monetization over time.

Complete Report Scope:

• By Component
  • Hardware
  • Software
  • Services
• By Deployment Mode
  • Conventional AI-Enhanced CT
  • Spectral CT
  • Photon-Counting CT
  • Interventional CT
• By Application
  • Oncology Diagnosis and Staging
  • Tumor Monitoring and Treatment Response
  • Radiation Therapy Planning Support
  • Research and Clinical Trials
• By End User
  • Hospitals
  • Diagnostic Imaging Centers
  • Cancer Treatment Centers
  • Academic and Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.4% share of the AI oncology vibe CT scanners market in 2025, which made it the largest regional base. The United States drives most of that demand through academic medical centers, community hospitals, and comprehensive cancer centers working within established reimbursement and capital planning structures. The National Cancer Institute estimated 2.04 million new cancer cases in the United States in 2025, and that case load continues to support strong imaging volumes. The region also saw dense regulatory activity between late 2025 and mid-2026, including major CT clearances tied to Philips Verida, GE HealthCare Photonova Spectra, Canon Medical Alphenix 4D CT, and Subtle Medical SubtleHD(CT) . Canada remains a steady procurement market through provincial modernization programs, while Mexico continues to offer room for growth in private hospital imaging.

Europe remains a strategically important part of the AI oncology vibe CT scanners market because centralized procurement, academic imaging leadership, and service-driven tenders shape vendor performance there. Germany, the United Kingdom, France, Italy, and Spain remain the main buying centers, and tender structures often favor suppliers with broad service networks and long support histories. United Imaging Healthcare said its Europe revenue rose nearly 50% in 2025 and that it secured CE certification for its RT systems under the EU MDR framework in early 2026, showing that Asian challengers are gaining traction beyond price competition alone. GE HealthCare also strengthened its imaging software position through the announced USD 2.3 billion Intelerad acquisition, while GDPR-related data governance expectations continue to add complexity to AI feature activation across multi-site health systems.

Asia Pacific is projected to grow at a 24.2% CAGR through 2031, which makes it the fastest-growing region in the AI oncology vibe CT scanners market. Growth across the region comes from a mix of hospital expansion, rising oncology demand, and faster commercialization of AI-enabled CT platforms in large national markets. China remains important because county-level hospital expansion supports volume demand, while local regulatory momentum encourages product strategies that align more closely with domestic AI capabilities. United Imaging Healthcare said Asia Pacific revenue grew more than 40% in 2025, which shows how strongly regional suppliers are scaling in their home markets and nearby export markets. Middle East and Africa and South America remain smaller in total size, but the draft still points to solid momentum from expanding public investment in diagnostic infrastructure and rising new orders in selected emerging markets.

1. Alphabet Inc. (Google Health / DeepMind)
2. Microsoft
3. NVIDIA
4. Siemens Healthineers
5. GE HealthCare Technologies Inc.
6. Koninklijke Philips
7. Roche
8. Tempus AI, Inc.
9. Aidoc Medical Ltd.
10. Qure.AI Technologies Private Limited
11. Heartflow
12. PathAI, Inc.
13. Paige.AI, Inc.
14. Ada Health GmbH
15. AliveCor
16. Butterfly Network, Inc.
17. Digital Diagnostics
18. Lunit
19. Ibex Medical Analytics Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Oncology Imaging Demand
  • 4.2.2 AI Assisted Protocol Optimization
  • 4.2.3 Photon Counting and Spectral Precision Gains
  • 4.2.4 Radiation Dose Reduction Pressure
  • 4.2.5 Oncology Workflow Automation and Triage
  • 4.2.6 Reimbursement Support for Quantitative Imaging
• 4.3 Market Restraints
  • 4.3.1 High Capital Cost of Premium CT Platforms
  • 4.3.2 Integration Burden Across PACS, RIS, and EHR Environments
  • 4.3.3 Clinical Validation and Regulatory Friction for AI Features
  • 4.3.4 Cybersecurity and Data Governance Concerns
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porters Five Forces

5 Market Size & Growth Forecasts

• 5.1 By Component
  • 5.1.1 Hardware
  • 5.1.2 Software
  • 5.1.3 Services
• 5.2 By Deployment Mode
  • 5.2.1 Conventional AI-Enhanced CT
  • 5.2.2 Spectral CT
  • 5.2.3 Photon-Counting CT
  • 5.2.4 Interventional CT
• 5.3 By Application
  • 5.3.1 Oncology Diagnosis and Staging
  • 5.3.2 Tumor Monitoring and Treatment Response
  • 5.3.3 Radiation Therapy Planning Support
  • 5.3.4 Research and Clinical Trials
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Imaging Centers
  • 5.4.3 Cancer Treatment Centers
  • 5.4.4 Academic and Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.4.6 Rest of Europe
  • 5.5.5 Asia-Pacific
    • 5.5.5.1 China
    • 5.5.5.2 India
    • 5.5.5.3 Japan
    • 5.5.5.4 South Korea
    • 5.5.5.5 Australia
    • 5.5.5.6 Rest of Asia-Pacific
  • 5.5.6 Middle East & Africa
    • 5.5.6.1 GCC
    • 5.5.6.2 South Africa
    • 5.5.6.3 Rest of Middle East and Africa
  • 5.5.7 South America
    • 5.5.7.1 Brazil
    • 5.5.7.2 Argentina
    • 5.5.7.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles
  • 6.3.1 Alphabet Inc. (Google Health / DeepMind)
  • 6.3.2 Microsoft Corporation
  • 6.3.3 NVIDIA Corporation
  • 6.3.4 Siemens Healthineers AG
  • 6.3.5 GE HealthCare Technologies Inc.
  • 6.3.6 Koninklijke Philips N.V.
  • 6.3.7 F. Hoffmann-La Roche Ltd
  • 6.3.8 Tempus AI, Inc.
  • 6.3.9 Aidoc Medical Ltd.
  • 6.3.10 Qure.ai Technologies Private Limited
  • 6.3.11 Heartflow, Inc.
  • 6.3.12 PathAI, Inc.
  • 6.3.13 Paige.AI, Inc.
  • 6.3.14 Ada Health GmbH
  • 6.3.15 AliveCor, Inc.
  • 6.3.16 Butterfly Network, Inc.
  • 6.3.17 Digital Diagnostics, Inc.
  • 6.3.18 Lunit Inc.
  • 6.3.19 Ibex Medical Analytics Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White Space and Unmet Need Assessment